3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Hodgkin Disease
3
Neutropenia
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Monocytic, Acute
2
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Teratoma
1
Solid Tumors
1
Sarcoma, Myeloid
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk
1
Osteosarcoma
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, AIDS-Related
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
26
130-nm albumin-bound paclitaxel
25
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
olaparib
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Taxes
19
Biopsy
19
Drug Therapy
16
atezolizumab
14
Nivolumab
14
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
pegylated granulocyte colony-stimulating factor
×
1 year
×
Clear all
NCT05076682
2025-12-03
Renaissance
Fudan University
Phase 2
Recruiting
80 enrolled